EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$3.17 +0.63% (+$0.02)
1M -30.92%
Market Cap $264.1M
P/E Ratio -
Div. Yield -
ROE 135.81%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
2/9Valuation
49 /100
Fair P/S 94.69x
P/B 1.59x
P/E N/A
Growth
22 /100
Declining Rev. growth 8.83%
Book val. growth 47.00%
EPS growth N/A
Profitability
17 /100
Weak Gross margin 41.77%
FCF margin 9,726.75%
Net margin 10,994.70%
Quality
0 /100
Poor ROIC 167.81%
Asset turnover 0.01x
ROE 135.81%
Debt
100 /100
Low Debt/Equity 0.13x
Current ratio 4.50x
Int. coverage N/A
Stability
39 /100
Moderate Beta 1.64x
Profitable years 0
Rev. volatility 19.37%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report